New pharmaceuticals in inflammatory bowel disease

Michał Łodyga; Piotr Eder; Witold Bartnik; Maciej Gonciarz; Maria Kłopocka; Krzysztof Linke; Ewa Małecka-Panas; Piotr Radwan; Grażyna Rydzewska

doi:10.5114/pg.2015.52702

Abstract

2/2015 vol. 10

Special paper

New pharmaceuticals in inflammatory bowel disease

Michał Łodyga

,

Piotr Eder

,

Witold Bartnik

,

Maciej Gonciarz

,

Maria Kłopocka

,

Krzysztof Linke

,

Ewa Małecka-Panas

,

Piotr Radwan

,

Grażyna Rydzewska

Prz Gastroenterol 2015; 10 (2): 57–60

DOI: https://doi.org/10.5114/pg.2015.52702

Online publish date: 2015/07/01

View full text

AMA

Łodyga M, Eder P, Bartnik W, et al. New pharmaceuticals in inflammatory bowel disease. Gastroenterology Review/Przegląd Gastroenterologiczny. 2015;10(2):57-60. doi:10.5114/pg.2015.52702.

APA

Łodyga, M., Eder, P., Bartnik, W., Gonciarz, M., Kłopocka, M., & Linke, K. et al. (2015). New pharmaceuticals in inflammatory bowel disease. Gastroenterology Review/Przegląd Gastroenterologiczny, 10(2), 57-60. https://doi.org/10.5114/pg.2015.52702

Chicago

Łodyga, Michał, Piotr Eder, Witold Bartnik, Maciej Gonciarz, Maria Kłopocka, Krzysztof Linke, and Ewa Małecka-Panas et al. 2015. "New pharmaceuticals in inflammatory bowel disease". Gastroenterology Review/Przegląd Gastroenterologiczny 10 (2): 57-60. doi:10.5114/pg.2015.52702.

Harvard

Łodyga, M., Eder, P., Bartnik, W., Gonciarz, M., Kłopocka, M., Linke, K., Małecka-Panas, E., Radwan, P., and Rydzewska, G. (2015). New pharmaceuticals in inflammatory bowel disease. Gastroenterology Review/Przegląd Gastroenterologiczny, 10(2), pp.57-60. https://doi.org/10.5114/pg.2015.52702

MLA

Łodyga, Michał et al. "New pharmaceuticals in inflammatory bowel disease." Gastroenterology Review/Przegląd Gastroenterologiczny, vol. 10, no. 2, 2015, pp. 57-60. doi:10.5114/pg.2015.52702.

Vancouver

Łodyga M, Eder P, Bartnik W, Gonciarz M, Kłopocka M, Linke K et al. New pharmaceuticals in inflammatory bowel disease. Gastroenterology Review/Przegląd Gastroenterologiczny. 2015;10(2):57-60. doi:10.5114/pg.2015.52702.

This paper complements the previously published Guidelines of the Working Group of the Polish Society of Gastroenterology and former National Consultant in Gastroenterology regarding the management of patients with Crohn’s disease and ulcerative colitis. Attention was focused on the new pharmaceutical recently registered for inflammatory bowel disease treatment.